Clinical Trials
26 trialsNCT04267848 2026-05-27
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05198830 2026-05-27
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07100080 2026-05-27
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06788912 2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05061550 2026-05-22
NeoCOAST-2
AstraZeneca
Phase 2 Recruiting
NCT06312137 2026-05-22
TroFuse-019
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06119581 2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT07063745 2026-05-18
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06793215 2026-05-11
Krascendo 2
Hoffmann-La Roche
Phase 3 Recruiting
NCT06632327 2026-05-08
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06217757 2026-05-05
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT05118854 2026-05-04
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05624996 2026-05-04
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT06623656 2026-04-21
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT06447662 2026-04-20
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT06561685 2026-04-20
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT07241767 2026-04-08
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT06538038 2026-03-27
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
NCT05633667 2026-03-17
VELOCITY-Lung
Gilead Sciences
Phase 2 Recruiting
NCT06162221 2026-03-09
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06484491 2026-01-30
HyDose
University Medical Center Groningen
Phase NA Recruiting
NCT04991025 2025-10-20
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04105270 2025-09-11
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT05609578 2025-08-17
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT06393816 2024-08-02
FIRST-NEC
Centre Leon Berard
Phase 2 Recruiting
NCT06177925 2023-12-20
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting